e-learning
resources
Berlin 2001
Sunday 23.09.2001
Genetics and cell biology of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differences of the hypoxia driven gene response in small (H69) and nonsmall (H23) cell lung carcinomas
F. Rose, P. Mahlik, B. Reichmann, D. Giannakakis, R. Vosswinkel, J. Appel, S. Krick, R. Schermuly, F. Grimminger, W. Seeger, J. Hanze (Giessen, Germany)
Source:
Annual Congress 2001 - Genetics and cell biology of lung cancer
Session:
Genetics and cell biology of lung cancer
Session type:
Oral Presentation
Number:
234
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Rose, P. Mahlik, B. Reichmann, D. Giannakakis, R. Vosswinkel, J. Appel, S. Krick, R. Schermuly, F. Grimminger, W. Seeger, J. Hanze (Giessen, Germany). Differences of the hypoxia driven gene response in small (H69) and nonsmall (H23) cell lung carcinomas. Eur Respir J 2001; 16: Suppl. 31, 234
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007
Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Humanized S.typhi flagellin (FliC) transfected non-small cell lung cancer (NSCLC) cells induce local inflammatory and necrotic changes in an experimental model
Source: Annual Congress 2011 - Phagocytes and dendritic cells
Year: 2011
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC).
Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research
Year: 2021
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Year: 2021
Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept